Company profilePharmaceutical#65 of 1,318 in Pakistan1 DRAP alert

PharmEvo Private Limited

Pharmaceutical company · 213 brands · 248 molecules

Ranked #4 of 70 companies in Cardiac Care

213 registered products 64 pharmaceutical brands 248 distinct molecules 1 DRAP alert

Company overview

213
registered products
64
pharmaceutical brands
248
distinct molecules
12
therapeutic classes
1
DRAP alerts

PharmEvo Private Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 213 product registrations across 248 distinct molecules. It is the 65th largest registrant in Pakistan by product count, and ranks 4th of 70 in Cardiac Care. Its portfolio is concentrated in Cardiac Care and Blood Glucose Lowering Drugs, Excluding Insulin. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by PharmEvo

272 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

165
ceilings with an approval date
6
not revised in 2+ years
2024
oldest approval year
20246
202573
202686
Longest without revision

Top molecules by brand count

Nutritional Supplement / Multivitamin9 brands
Valsartan8 brands
Telmisartan8 brands
Amlodipine7 brands
Metformin6 brands
Irbesartan6 brands
Glimepiride5 brands
Omeprazole4 brands

Therapeutic classes

Cardiac Care · 16Blood Glucose Lowering Drugs, Excluding Insulin · 12Angiotensin-Ii Antagonists, Combinations · 12Neuro · 7Diabetes · 6Antivirals For Systemic Use · 6Other Beta-Lactam, Cephalosporins & Penems · 5Antidepressants · 5Antithrombotic Agents · 5Blood Conditions · 5Antineoplastics · 4Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 3

Conditions treated

Hypertension · 11Oral Agents · 6Blood Clot/Thrombotic Disorder · 4Anxiety/Depression/Insomnia · 3Ulcer/Reflux/Flatulence/Acidity · 2Pain Killers · 2High Cholestrol · 2Epilepsy/Convulsion · 2Heart Failure · 2Gout · 1General Infections · 1Asthma/Allergy · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official184 products · Rs 66.78 – Rs 144,288.97
DVAGO129 products · Rs 28.5 – Rs 2,884
Servaid100 products · Rs 123.2 – Rs 1,725
Median across source: Rs 370.44

Regulatory record

1 alert in the DRAP feed we track.

Recall Alert: Drug Product; Telsarta 40mg Tablets (Batch # 2B151) by M/s PharmEvo Pharmace
2022-11-04

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GETZ PHARMA PAKISTAN (PVT) LTD. holds 204 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
NABIQASIM INDUSTRIES (PVT) LTD. holds 150 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir
HILTON PHARMA (PVT) LIMITED holds 105 molecules not in this portfolio
15 Microgram Of Each Strain H1AlprazolamAlum Hydroxide GelAmodiaquineArtemetherArtemether/Lumafantrine

Get the full profile for PharmEvo

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.